[1. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin - an updated overview. Nature Clinical Practice Oncology. 2006;3:152-154.10.1038/ncponc0451]Search in Google Scholar
[2. Nagy J, Kiss I. Az eritropoetin pleiotrop hatásai. LAM. 2007;17(12):861-867.]Search in Google Scholar
[3. Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron defi ciency and the specifi c role of i.v. iron. Annals of Oncology. 2012;23:1954-1962.10.1093/annonc/mds112]Search in Google Scholar
[4. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD007303. DOI: 10.1002/14651858.CD007303.pub2.10.1002/14651858.CD007303.pub2]Search in Google Scholar
[5. Barrett-Lee PJ, Ludwig H, Birgegård G. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anemia Survey. Oncology. 2006;70:34-48.10.1159/000091675]Search in Google Scholar
[6. Birgegård G, Aapro MS, Bokemeyer C. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology. 2005;68(Suppl 1): 3-11.10.1159/000083128]Search in Google Scholar
[7. Thomas ML. Impact of anemia and fatigue on quality of life in cancer patients; A brief review. Med Oncol. 1998;15:53-57.]Search in Google Scholar
[8. Shasha D, George MJ, Harrison LB. Once weekly dosing of epoetin increases hemoglobin and quality of life in anemic cancer patient receiving radiation therapy either concomitently or sequentially with chemoterapy. Cancer. 2003;98:1072-1079.10.1002/cncr.11616]Search in Google Scholar
[9. Miller Carole B, Jones RJ, Piantados S, Abeloff MD, Spivak JL. Decreased Erythropoietin Response in Patients with the Anemia of Cancer, M.D. N Engl J Med. 1990;322:1689-1692.]Search in Google Scholar
[10. Engert A, Josting A, Haverkamp H, et al. Epoetin Alfa in Patients With Advenced-Stage Hodgkin’s Lymphoma. Results of the Randomized Placebo- Controled GHSG, HD15 EPO Trial. J Clin Oncol. 2010;28(13):2239-2245.10.1200/JCO.2009.25.1835]Search in Google Scholar
[11. Spivak JL, Gascon P, Ludwig H. Anemia Management in Oncology and Hematology. The Oncologist. 2009;14(S1):43-56.10.1634/theoncologist.2009-S1-43]Search in Google Scholar
[12. Coiffi er B. Anemia associated with non-platinum chemotherapy (CT) for Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL). European Journal of Cancer. 1999;35:S331.10.1016/S0959-8049(99)81747-X]Search in Google Scholar
[13. Campos MPO, Hassan BJ, Riechelmann R, Del Giglio A. Cancer-related fatigue: a practical review. AnnOncol. 2011;22(6):1273-1279.10.1093/annonc/mdq45821325448]Search in Google Scholar
[14. Littlewood TJ. Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematological Oncology. 2001;19(1):19-30.10.1002/hon.66311276043]Search in Google Scholar
[15. Truong Pauline T, Parhar Tarnjit BS, Hart J, Alexander Cheryl, Wai Elaine S. Population-Based Analysis of the Frequency of Anemia and its Management Before and During Chemotherapy in Patients With Malignant Lymphoma. American Journal of Clinical Oncology. 2010;33(5):465-468.10.1097/COC.0b013e3181b4b14719935386]Search in Google Scholar
[16. Pirker R. Safety considerations for erythropoietin treatment in patients with cancer, Expert Opinion on Drug Safety. 2007;6(1):63-69.]Search in Google Scholar
[17. Deger M, Eisterer W, Kutikova Lucie, Salek S. Hemoglobin level at initiation of darbopoetin alfa: impact on need for transfusion and associated costs in chemoterapy-induced anemia treatment in Europe. Supportive Care in Cancer. 2013;21:485-493.10.1007/s00520-012-1538-0353802222825456]Search in Google Scholar
[18. Schrijvers D, Samblanx H, Roila F. Erythropoiesis stimulating agents in the treatment of cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol. 2010;21(Suppl 5):244-247.10.1093/annonc/mdq20220555090]Search in Google Scholar
[19. Carson JL, Grossmann BJ, Kleinmann S, et al. Red blood cell transfusion: a clinical practice guaidline from the AABB. Ann Intern Med. 2012;157: 49-58.10.7326/0003-4819-157-1-201206190-0042922751760]Search in Google Scholar
[20. Eisterer W, Hussl C, Erb H, et al. Evaluating the transfusion rate with darbepoetin alfa 500 microg every 3 weeks in anemic cancer patients receiving chemotherapy. Cur Med Res Opin. 2011;27:355-363.10.1185/03007995.2010.54213421166611]Search in Google Scholar
[21. Canon JL, Vansteenkiste J, Hedenus M, et al. Transfusion risk in cancer patients with chemoterapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobine level of <9 /g/dL versus 9 to 10g/ dL versus ≥ 10g/dL: an exploratory analysis of a phase 3 trial. Med Oncol. 2011, doi: 10.1007/s12032-011-0103-x. 10.1007/s12032-011-0103-x22081263]Search in Google Scholar